2-bromo-3-bromomethyl-6,7-dimethylquinoline | 182052-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-bromo-3-bromomethyl-6,7-dimethylquinoline
• 英文别名: 2-Bromo-3-(bromomethyl)-6,7-dimethylquinoline
• CAS: 182052-70-6
• 化学式: C₁₂H₁₁Br₂N
• 分子量: 329.034
• InChiKey: PBVUFSYJMFPBMI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-bromo-3-bromomethyl-6,7-dimethylquinoline 在 盐酸 、 palladium diacetate 、 三(2-呋喃基)膦 、 2,4-滴二甲胺盐 、 铜 、 锌 作用下， 以 水 、 甲苯 为溶剂， 反应 11.0h， 生成 LAS 333
  参考文献：
  名称：

  New heteroaryl-spaced phosphono α-amino acids are competitive NMDA antagonists with analgesic activity

  摘要：

  The synthesis and the NMDA receptor binding affinities of alpha-amino-3-(phosphonomethyl)-2-naphthalene-propanoic acid, alpha-amino-3-(phosphonomethyl)-2-benzofuranpropanoic acid, a series of substituted (R)-alpha-amino-3-(phosphonomethyl)-2-quinolinepropanoic acids, (R)-alpha-amino-3-(phosphonomethyl)-1,8-naphthyridine-2-propanoic acid and (R)-alpha-amino-3-(phosphonomethyl)-1,6-naphthyridine-2-propanoic acid are reported. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00288-0
• 作为产物：
  描述：

  3-氯-N-(3,4-二甲基苯基)丙酰胺 在 三氯氧磷 、 三溴氧磷 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 2-bromo-3-bromomethyl-6,7-dimethylquinoline
  参考文献：
  名称：

  New heteroaryl-spaced phosphono α-amino acids are competitive NMDA antagonists with analgesic activity

  摘要：

  The synthesis and the NMDA receptor binding affinities of alpha-amino-3-(phosphonomethyl)-2-naphthalene-propanoic acid, alpha-amino-3-(phosphonomethyl)-2-benzofuranpropanoic acid, a series of substituted (R)-alpha-amino-3-(phosphonomethyl)-2-quinolinepropanoic acids, (R)-alpha-amino-3-(phosphonomethyl)-1,8-naphthyridine-2-propanoic acid and (R)-alpha-amino-3-(phosphonomethyl)-1,6-naphthyridine-2-propanoic acid are reported. Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00288-0

文献信息

• Synthesis and pharmacological evaluation of novel non-lactone analogues of camptothecin
  作者：Patrick Hautefaye、Bernard Cimetière、Alain Pierré、Stéphane Léonce、John Hickman、William Laine、Christian Bailly、Gilbert Lavielle

  DOI：10.1016/s0960-894x(03)00534-1

  日期：2003.8

  Ten novel camptothecin (CPT) derivatives devoid of the lactone function in the E-ring were synthesized and evaluated as anticancer agents. Several of these CPT analogues bearing a five-membered E-ring are potent inhibitors of the DNA relaxation and cleavage reactions catalyzed by topoisomerase I and exhibit promising cytotoxic activities with IC(50) values in the nM range. This is the first successful

  合成了十个在E环中没有内酯功能的新型喜树碱（CPT）衍生物，并将其评估为抗癌剂。这些带有五元E环的CPT类似物中的几种是拓扑异构酶I催化的DNA松弛和裂解反应的有效抑制剂，并显示出有希望的细胞毒活性，其IC（50）值在nM范围内。这是无内酯的CPT的第一个成功设计，因此为拓扑异构酶I靶向抗肿瘤药的开发提供了新途径。
• New camptothecin analogue compounds
  申请人：——

  公开号：US20020077325A1

  公开（公告）日：2002-06-20

  Compound of formula (I): 1 wherein: n is 0, 1 or 2, R 1 , R 2 , R 3 , R 4 and R 5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH 2 ) p —NR a R b and —O—C(O)—N—R a R b , with p, R a and R b being as defined in the description, or two adjacent groups R 2 , R 3 , R 4 and R 5 together form a group —O—(CH 2 ) t —O, t being an integer from 1 to 3), R 60 , R 70n , R 80 and R 90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R 61 , R 71n , R 81 and R 91 represent a hydrogen atom , alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous diseases.

  化合物的式子（I）：其中：n为0、1或2，R1、R2、R3、R4和R5选择自氢、卤素、烷基、烯基、炔基、全氟烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基（可选择性取代），以及(CH2)p-NRaRb和-O-C(O)-N-RaRb这些基团，其中p、Ra和Rb如描述中所定义，或者相邻的两个基团R2、R3、R4和R5共同形成一个-O-(CH2)t-O的基团，其中t为1到3的整数。R60、R70n、R80和R90代表氢原子、羟基、烷氧基或描述中定义的O-(CO)-X或O-(CO)-NXW基团。R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基，或者成对地共同形成键或环氧丙烷基团，或者两个基团共同形成一个羰基团。含有这些化合物的药品对于治疗癌症疾病是有用的。
• New campothecin analogue compounds
  申请人：——

  公开号：US20030105109A1

  公开（公告）日：2003-06-05

  Compound of formula (I): 1 wherein: n is 0, 1 or 2, R 1 represents (C 3 -C 11 )cycloalkyl or (C 3 -C 11 )cycloalkylalkyl, R 2 , R 3 , R 4 and R 5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH 2 ) p —N a R b and —O—C(O)—N—R a R b , with p, R a and R b being as defined in the description, or two adjacent groups R 2 , R 3 , R 4 and R 5 together form a group —O—(CH 2 ) t —O, t being an integer from 1 to 3, R 60 , R 70n , R 80 and R 90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R 61 , R 71n , R 81 , and R 91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous disesases.

  式(I)的化合物： 其中： n为0、1或2， R1代表(C3-C11)环烷基或(C3-C11)环烷基烷基， R2、R3、R4和R5选择自氢、卤素、烷基、烯基、炔基、全卤烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基（可选地取代）和(CH2)p—NaRb和—O—C(O)—N—RaRb基团，其中p、Ra和Rb如描述中定义，或者相邻的两个基团R2、R3、R4和R5组成—O—(CH2)t—O基团，其中t为1到3的整数， R60、R70n、R80和R90代表氢原子、羟基、烷氧基，或者如描述中所定义的O—(CO)—X或O—(CO)—NXW基团， R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基，或成对地共同形成键或环氧基团，或两个基团共同形成氧基团。 含有该化合物的药物对治疗癌症有用。
• Camptothecin analogue compounds
  申请人：Les Laboratoires Servier

  公开号：US06699876B2

  公开（公告）日：2004-03-02

  Compound of formula (I): wherein: n is 0, 1 or 2, R1 represents (C3-C11)cycloalkyl or (C3-C11)cycloalkylalkyl, R2, R3, R4 and R5 are selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, perhaloalkyl, cycloalkyl, cycloalkylalkyl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, alkoxycarbonyl, acyloxy, carboxy, nitro, cyano, aminocarbonyl (optionally substituted), and the groups (CH2)p—NaRb and —O—C(O)—N—RaRb, with p, Ra and Rb being as defined in the description, or two adjacent groups R2, R3, R4 and R5 together form a group —O—(CH2)t—O, t being integer from 1 to 3, R60, R70n, R80 and R90 represent a hydrogen atom, a hydroxy group, an alkoxy group, or an O—(CO)—X or O—(CO)—NXW group as defined in the description, R61, R71n, R81, and R91 represent a hydrogen atom, alkyl, alkenyl or alkynyl, or taken in pairs together form a bond or an oxirane group, or two groups together form an oxo group. and medicinal products containing the same are useful for the treatment of cancerous disesases.

  化合物的化学式为（I）：其中，n为0、1或2，R1代表（C3-C11）环烷基或（C3-C11）环烷基烷基，R2、R3、R4和R5选自氢、卤素、烷基、烯基、炔基、全氟烷基、环烷基、环烷基烷基、羟基、羟基烷基、烷氧基、烷氧基烷基、烷氧羰基、酰氧基、羧基、硝基、氰基、氨基羰基（可选取代）和（CH2）p-NaRb和-O-C（O）-N-RaRb等基团，其中p、Ra和Rb的定义如说明书所述，或者相邻的两个基团R2、R3、R4和R5组成-O-（CH2）t-O基团，其中t为1到3的整数，R60、R70n、R80和R90代表氢原子、羟基、烷氧基或如说明书中所定义的O-（CO）-X或O-（CO）-NXW基团，R61、R71n、R81和R91代表氢原子、烷基、烯基或炔基，或成对地结合成键或环氧基团，或两个基团共同形成一个酮基团。含有这些化合物的药物对治疗癌症有用。
• Nouveaux composés analogues de la camptothécine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
  申请人：LES LABORATOIRES SERVIER

  公开号：EP1101765B1

  公开（公告）日：2002-08-14